Table 1.
Activity of KRAS G12C inhibitors in early phase clinical trials; results of phases I/II with sotorasib or adagrasib [14,46].
| KRAS G12C Inhibitors | AMG 510 (Sotorasib) | MRTX849 (Adagrasib) |
|---|---|---|
| Reference | [47] | [14] |
| Clinical trial | Phase II CodeBreaK 100 |
Phase I/II KRYSTAL-1 |
| Patient population | KRAS G12C mutated advanced cancers | KRAS G12C mutated advanced cancers |
| Study population (n) | 59 NSCLC | 79 NSCLC, 51 evaluable |
| ORR (%) | 37 (CR 3.2) | 45 |
| DCR (%) | 80.6 | 96 |
| mDOR (mo) | 11.1 | NR |
| mPFS (mo) | 6.8 | NR |
| mOS (mo) | 12.5 | NR |
ORR: overall response rate; CR: complete response; DCR: disease-control rate; mDOR: median duration of response; mPFS: median progression-free survival; mOS: median overall survival; and NR: not reported.